^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Free radical stimulant

    Related drugs:
    8d
    Efficacy and safety of artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum in Eritrea in 2022 (ACTRN12625001329459)
    P4, N=352, Completed, Ministry of Health
    New P4 trial
    16d
    SAFIRE: Safety of Antimalarials in the FIRst trimEster (clinicaltrials.gov)
    P3, N=1510, Recruiting, Liverpool School of Tropical Medicine | Not yet recruiting --> Recruiting | Initiation date: Jul 2025 --> Sep 2025
    Enrollment open • Trial initiation date • Head-to-Head
    17d
    FD-TACT: A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines (clinicaltrials.gov)
    P3, N=1680, Recruiting, University of Oxford | Not yet recruiting --> Recruiting | Trial completion date: May 2025 --> Jul 2026 | Trial primary completion date: Nov 2024 --> Jul 2026
    Enrollment open • Trial completion date • Trial primary completion date • Head-to-Head
    17d
    DeTACT-Africa: A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs. (clinicaltrials.gov)
    P3, N=2583, Completed, University of Oxford | Recruiting --> Completed
    Trial completion • Head-to-Head
    24d
    NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=24 --> 34
    Enrollment closed • Enrollment change
    |
    Hensify (crystalline hafnium oxide)
    1m
    NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=40, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    Hensify (crystalline hafnium oxide)
    1m
    OPTIMAH: OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa (clinicaltrials.gov)
    P4, N=380, Not yet recruiting, Yale University | Trial completion date: Sep 2027 --> Dec 2027 | Initiation date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2027 --> Dec 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    1m
    NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Oct 2025 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    carboplatin • paclitaxel • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical • Hensify (crystalline hafnium oxide)
    1m
    Study 1100: NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy (clinicaltrials.gov)
    P1, N=145, Active, not recruiting, Nanobiotix | Recruiting --> Active, not recruiting | Trial completion date: May 2028 --> Aug 2027
    Enrollment closed • Trial completion date
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Hensify (crystalline hafnium oxide)
    1m
    A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Johnson & Johnson Enterprise Innovation Inc.
    New P1 trial
    |
    Hensify (crystalline hafnium oxide)
    2ms
    Study Evaluating the Efficacy and Safety of Artesunate (clinicaltrials.gov)
    P2, N=90, Recruiting, Amivas Inc. | Not yet recruiting --> Recruiting | Initiation date: May 2025 --> Aug 2025
    Enrollment open • Trial initiation date
    |
    Valcyte (valganciclovir)
    2ms
    ART_CIN_II: Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3) (clinicaltrials.gov)
    P2, N=78, Recruiting, Frantz Viral Therapeutics, LLC | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial completion date • Trial primary completion date